

Attorney's Docket No. 5656-21



BET
9.5.02 3762
#41 IDS
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ideker et al.

Serial No.: 10/071,269

Filed: February 8, 2002

For: METHODS AND DEVICES FOR TREATING ARRHYTHMIAS USING
DEFIBRILLATION SHOCKS

Confirmation No.: 9014

Group Art Unit: 3763

August 26, 2002

Commissioner for Patents
Washington, DC 20231


INFORMATION DISCLOSURE STATEMENT

RECEIVED
SEP 03 2002
TECHNOLOGY CENTER R3700

Sir:

Attached is a form PTO-1449, together with a copy of the identified documents. This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.


Respectfully submitted,


Jarett K. Abramson
Registration No. 47,376

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, North Carolina 27627
Telephone (919) 854-1400
Facsimile (919) 854-1401

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 26, 2002.


Susan E. Freedman
Date of Signature: August 26, 2002

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 5656-21		Serial No. 10/071,269	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				Applicants: Ideker et al.			
				Filing Date: February 8, 2002			GAU:
U.S. PATENT DOCUMENTS							
Examiner Initials	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	6,275,730	08/14/01	KenKnight et al.	607	5	
	2	6,246,908	06/12/01	Chattipakorn et al.	607	5	
	3	5,987,354	11/16/99	Cooper et al.	607	5	
		4,830,006	05/16/89	Haluska et al.	128	419 PG	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Chattipakorn et al., "Origin of the earliest activation after ventricular defibrillation: Insight from a 3-dimensional cardiac mapping", <i>PACE: NASPE Abstracts</i> , Vol. 24, April 2001, p. 669					
	6	Chattipakorn et al., "Three-dimension cardiac mapping of the earliest activation following upper limit of vulnerability shocks", <i>PACE: NASP Abstracts</i> , Vol. 24, April 2001, p. 561					
	7	Chattipakorn et al., "Mechanism of Defibrillation" In <i>Fighting Sudden Cardiac Death: A Worldwide Challenge</i> , Futura Publishing Co., 2000, pp. 593-615					
	8	Meisel et al., "Transvenous biventricular defibrillation", <i>Am J Cardiol</i> , Vol. 86, No. 9A, November 2, 2000, pp. K76-K85					
	9	Chattipakorn et al, "Prediction of defibrillation outcome by epicardial activation patterns following shocks near the defibrillation threshold", <i>J. Cardiovasc. Electrophysiol</i> , Vol. 11, No. 9, September 2000, pp. 1014-1021					
	10	Ideker et al., "Defibrillation Mechanisms: The Parable of the Blind Men and the Elephant", <i>J. Cardiovasc. Electrophysiol</i> , Vol. 11, No. 9, September 2000, pp. 1008-1013					
	11	KenKnight et al., "Marked reduction of ventricular defibrillation threshold by application of an auxiliary shock to a catheter electrode in the left posterior coronary vein of dogs", <i>J Cardiovasc Electrophysiol</i> , Vol. 11, No. 8, August 2000, pp. 900-906					
	12	Roberts et al., "The middle cardiac vein--a novel pathway to reduce the defibrillation threshold", <i>J Interv Card Electrophysiol</i> , Vol. 3, 1999, pp. 55-60					
	13	Anderson et al., "KN-93, an Inhibitor of Multifunctional Ca ⁺⁺ /Calmodulin-Dependent Protein Kinase, Decreases Early Afterdepolarizations in Rabbit Heart", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 287, No. 3, 1998, pp. 996-1006					
	14	Usui et al., "Epicardial sock mapping following monophasic and biphasic shocks of equal voltage with an endocardial lead system", <i>J. Cardiovasc. Electrophysiol</i> , Vol. 7, No. 4, April 1996, pp. 322-334					
	15	Verduyn et al., "The Effect of Flunarizine and Ryanodine on Acquired Torsades de Pointes Arrhythmias in the Intact Canine Heart", <i>J Cardiovasc Electrophysiol</i> , Vol. 6, No. 3, March 1995, pp. 189-200					
	16	Li et al., "Defibrillation shocks produce different effects on Purkinje fibers and ventricular muscle: implications for successful defibrillation, refrillation and postshock arrhythmia", <i>J. Am. Coll. Cardiol.</i> , Vol. 22, No. 2, August 1993, pp. 607-614					
	17	Billman, "The calcium channel antagonist, flunarizine, protects against ventricular fibrillation", <i>European Journal of Pharmacology</i> , Vol. 212, 1992, pp. 231-235					
	18	Vos et al., "Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine", <i>J Cardiovasc Pharmacol.</i> , Vol. 19, No. 5, 1992, pp. 682-690					
	19	Almotrefi, "Investigations of the antifibrillatory activity of flunarizine and lidoflazine in isolated hearts of rabbits and guinea pigs", <i>Fundam Clin Pharmacol</i> , Volume 4, 1990, pp. 503-510					
	20	Vos et al., "Flunarizine allows differentiation between mechanisms of arrhythmias in the intact heart", <i>Circulation</i> , Vol. 81, No. 1, January 1990, pp. 343-349					
	21	Vos et al., "Termination of ouabain-induced ventricular tachycardia by flunarizine in conscious dogs", <i>Eur J Pharmacol</i> , Vol. 165, 1989, pp. 139-145					
	22	Vos et al., "The effect of an entrainment protocol on Ouabain-induced ventricular tachycardia", <i>PACE</i> , Vol. 12, 1989, pp. 1485-1493					
	23	Shibata et al., "Epicardial activation following unsuccessful defibrillation shocks in dogs" <i>Am. J. Physiol</i> , Vol. 255, 1988, pp. H902-H909					
	24	Gulati et al., "Pharmacodynamic studies with flunarizine, a calcium influx blocker", Medline Abstract, <i>Arch Int. Pharmacodyn Ther</i> , Vol. 263, May 1983, pp. 17-27					

Examiner: _____ Date Considered: _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.